Woo et al. indicated that, like TIGIT, LAG-3 may act synergistically with PD-1 to promote tumoural immune escape, and that combination anti-LAG-3/anti-PD-1 immunotherapy appears to be a legitimate strategy for cancer immunotherapy [64]. The gene discussed is LAG3; the disease is cancer.